ESG risk score 42.41
Environmental score -
Social score -
Governance score -
ESG risk category Severe
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Cue Biopharma Inc.
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol CUE:xnas
Currency USD
NASDAQ (Small cap)
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) 177.12%
1 year 7.21%
3 years -77.19%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -5.53
Volatility (30 days) 130.05%
Data provided by
Analyst consensus
Average rating Buy
Rating Analysts
Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Target price 115
Implied return 352.93%
Last updated 06-Feb-2026
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Sector Healthcare
Industry -
Market cap 0.112989146bn
Data provided by /
/ Frequently asked questions
To buy Cue Biopharma Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Cue Biopharma Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Cue Biopharma Inc. is CUE:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Cue Biopharma Inc. has its primary listing on NASDAQ (Small cap). You can trade Cue Biopharma Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Cue Biopharma Inc. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Cue Biopharma Inc. as part of a broader investment portfolio.